|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, October 09, 2018 ) Growing incidence of oncology diseases is expected to boost the demand for next generation cancer diagnostic tests market. However, lack of sufficient reimbursement policies for novel technologies and stringent regulatory procedures are the major factors that can hamper the global next generation cancer diagnostics market growth over the forecast period.
The largest segment of the global market for next generation cancer diagnostics is Blood-born cancers. Asia Pacific is likely to be one of the fastest growing regions of this sector and is anticipated to grow at a lucrative rate. A largely untouched market base which has exhibited technological advancements in healthcare research during the past decade is responsible for rapid growth in this region.
Some of the key players in the global Next Generation Cancer Diagnostics market are Thermo Fisher Scientific, Inc., Roche, Philips Electronics NV, Perkin Elmer Inc., Novartis AG, Lab-on-a-chip, Illumina, Inc., Agilent Technologies Inc, Siemens Healthcare, Johnson & Johnson, Hologic Inc., GE Healthcare, C.R. Bard, Inc and Abbot.
Request sample copy at: https://www.reportsweb.com/inquiry&RW0001216369/sample
Next Generation Cancer Diagnostics market is estimated at $2.95 billion in 2015 and is expected to grow at a CAGR of 32.6% to reach $20.93 billion by 2022.
The cancer diagnostics industry is projected to witness lucrative growth in the next few years due to the increasing number of technologically advanced products providing accurate test results in the field of diagnostics. Additionally, they also help with therapeutic monitoring and early diagnosis of cancer. Significant improvements observed in the shift from traditional laboratory testing to rapid point of care testing (POC) drive this market.
Commercialization of products such as diagnostic kits, instruments, reagents, and consumables plays a role as well. The decreasing cost of genetic sequencing, rising incidence of cancer, increasing interest in the microfluidic hip technology, and the use of circulating tumor cells (CTCs) in cancer management have also aided the development of the next-generation cancer diagnostics market.
Have any query? Enquire about report at: https://www.reportsweb.com/inquiry&RW0001216369/buying
Fundamentals of Table of Content:
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.5 Market by Application
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Next generation cancer diagnostics Market Size
2.2 Next generation cancer diagnostics Growth Trends by Regions
2.3 Industry Trends
3 Market Share by Key Players
3.1 Next generation cancer diagnostics Market Size by Manufacturers
3.2 Next generation cancer diagnostics Key Players Head office and Area Served
3.3 Key Players Next generation cancer diagnostics Product/Solution/Service
3.4 Date of Enter into Next generation cancer diagnostics Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Next generation cancer diagnostics Sales by Product
4.2 Global Next generation cancer diagnostics Revenue by Product
4.3 Next generation cancer diagnostics Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Next generation cancer diagnostics Breakdown Data by End User
Get more information at: https://www.reportsweb.com/inquiry&RW0001216369/discount
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
